Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of ...
BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States Study shows >95% success rate, validating ...
THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of patient enrollment in the PROGRESS (A Phase 2b, Dose-ranging, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback